Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 1
5(83.3%)
Phase 3
1(16.7%)
6Total
Phase 1(5)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT06743126Phase 3Recruiting

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Role: lead

NCT03686124Phase 1Recruiting

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

Role: lead

NCT06946225Phase 1Recruiting

ACTengine® IMA203 Combined With mRNA-4203

Role: lead

NCT02876510Phase 1Completed

ACTolog in Patients With Solid Cancers

Role: lead

NCT03760952Completed

Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling

Role: lead

NCT03441100Phase 1Completed

TCR-engineered T Cells in Solid Tumors: IMA202-101

Role: lead

NCT03247309Phase 1Completed

TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101)

Role: lead

All 7 trials loaded